FOSUN PHARMA's Controlled Subsidiary Receives Clinical Trial Approval for Drug HLX316

Stock News03-09

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) has announced that its controlled subsidiary, Shanghai Henlius Biotech, Inc., along with its own controlled subsidiaries (collectively referred to as "Henlius"), recently received approval from the National Medical Products Administration. The approval grants permission to conduct a Phase I clinical trial of HLX316 for injection, a targeted B7-H3 sialidase Fc fusion protein, for the treatment of advanced/metastatic solid tumors. Henlius plans to initiate the related clinical research in China once conditions are met. HLX316 is a novel, first-in-class, targeted B7-H3 sialidase heterodimer developed by the group through the fusion of a B7-H3-targeting heavy-chain-only antibody variable domain (VHH) with a licensed sialidase bifunctional fusion protein. It is intended for the treatment of advanced/metastatic solid tumors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120820854?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 17:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120820854","market":"us","top_or_hot":-1,"title":"FOSUN PHARMA's Controlled Subsidiary Receives Clinical Trial Approval for Drug HLX316","media":"Stock News","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) has announced that its controlled subsidiary, Shanghai Henlius Biotech, Inc., along with its own controlled subsidiaries (collectively referred to as \"Henlius\"), recently received approval from the National Medical Products Administration. The approval grants permission to conduct a Phase I clinical trial of HLX316 for injection, a targeted B7-H3 sialidase Fc fusion protein, for the treatment of advanced/metastatic solid tumors. Henlius plans to initiate the related clinical research in China once conditions are met. HLX316 is a novel, first-in-class, targeted B7-H3 sialidase heterodimer developed by the group through the fusion of a B7-H3-targeting heavy-chain-only antibody variable domain (VHH) with a licensed sialidase bifunctional fusion protein. It is intended for the treatment of advanced/metastatic solid tumors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA's Controlled Subsidiary Receives Clinical Trial Approval for Drug HLX316</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA's Controlled Subsidiary Receives Clinical Trial Approval for Drug HLX316\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-09 17:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) has announced that its controlled subsidiary, Shanghai Henlius Biotech, Inc., along with its own controlled subsidiaries (collectively referred to as \"Henlius\"), recently received approval from the National Medical Products Administration. The approval grants permission to conduct a Phase I clinical trial of HLX316 for injection, a targeted B7-H3 sialidase Fc fusion protein, for the treatment of advanced/metastatic solid tumors. Henlius plans to initiate the related clinical research in China once conditions are met. HLX316 is a novel, first-in-class, targeted B7-H3 sialidase heterodimer developed by the group through the fusion of a B7-H3-targeting heavy-chain-only antibody variable domain (VHH) with a licensed sialidase bifunctional fusion protein. It is intended for the treatment of advanced/metastatic solid tumors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"","article_id":"1120820854","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120820854","pubTimestamp":1773049907,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) has announced that its controlled subsidiary, Shanghai Henlius Biotech, Inc., along with its own controlled subsidiaries (collectively...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0028":"国家队","BK0239":"医药制造","BK0060":"抗癌","BK0187":"一线龙头","BK0183":"MSCI概念","BK1515":"抗疫概念","BK1191":"制药","BK0188":"融资融券","BK0096":"民营医院","BK1593":"医美概念股","BK0012":"证金概念","BK0175":"白马股","BK0196":"行业龙头","02196":"复星医药"},"translate_title":"复星医药控股子公司获药物HLX316临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) has announced that its controlled subsidiary, Shanghai Henlius Biotech, Inc., along with its own controlled subsidiaries (collectively referred to as \"Henlius\"), recently received approval from the National Medical Products Administration. The approval grants permission to conduct a Phase I clinical trial of HLX316 for injection, a targeted B7-H3 sialidase Fc fusion protein, for the treatment of advanced/metastatic solid tumors. Henlius plans to initiate the related clinical research in China once conditions are met. HLX316 is a novel, first-in-class, targeted B7-H3 sialidase heterodimer developed by the group through the fusion of a B7-H3-targeting heavy-chain-only antibody variable domain (VHH) with a licensed sialidase bifunctional fusion protein. It is intended for the treatment of advanced/metastatic solid tumors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120820854","isCrawlerRequest":true}